Primary myelofibrosis (PMF) is associated with abnormal trafficking pattems of CD34+ ceils, wtiicli fias been attributed to dysregulation of the bone marrow microenvironment due to downregulation of the chemokine receptor, CXCR4 by CD34+ cells, production by PIVIF cells of a variety proteases including matrix metaIloproteinase-9 (i /IMP-9), neutrophil elastase (NE), cathepsin G (CG) and CD26, which disrupt the interactions between chemoldne receptors and integrins expressed by CD34+ cells and chemokines and matrix proteins produced by the manrow microenvironment, distortion of the marrow architecture by fibrosis and incrased marrow microvessel density. Furthermore, the marrows of these patients are exposed to a variety of cytokines many of which have a profound effect on both cells belonging to the maaow microenvironment and hematopoietic stem cells (HSC)/hematopoietic progenitor cells (HPC). We hypothesize that distinctive hematopoietic microenvironments are present in the spleen and marrow of PMF patients which differentially influence PMF-HSC/HPC proliferation and trafficking thereby determining disease phenotype and progression. This hypothesis is based upon the assumption that stem cell niches within the marrow and spleen of PMF patients which nurture and determine stem cell fate decisions are dysfunctional as a consequence of their close interactions with PMF cells and that such cancer activates niches are capable of influencing PMF HSC/HPC behavior. In order to test this hypothesis the following specific aims will be pursued: 1: We will test the hypothesis that the hematopoietic microenvironment in the marrows and spleens of MPN MF patients each have distinctive charateristics which determine CD34+ cell trafficing patterns. 2) We will test the hypothesis that the interplay between PMF and their progeny and components of the microenvironment within the marrow leads to dysregulated cancer niches allowing HSC/HPC to escape the tightly regulated proliferation signals which normally occur. These dysfunctional hematopoietic niches in PMF ultimately contribute to depletion of marrow HSC/HPS and the survival of malignant clones endowed with a higher affinity for niches within the spleen resulting in disease progression.

Public Health Relevance

We hypothesize that distinctive hematopoietic microenvironments are present in the spleen and man-ow of PMF patients which differentially influence PMF-HSC/HPC proliferation. With the completion of these studies we anticipate a paradigm shift in the treatment of MPN MF moving beyond the exclusive use of agents to target cells belonging to the malignant clone to a strategy combining the use of such drugs with agents that interfere with the dysfunctional hematonopoietic microenvironment

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Icahn School of Medicine at Mount Sinai
New York
United States
Zip Code
Wang, Xiaoli; Hu, Cing Siang; Petersen, Bruce et al. (2018) Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells. Blood Adv 2:2378-2388
Zimran, Eran; Tripodi, Joseph; Rampal, Raajit et al. (2018) Genomic characterization of spleens in patients with myelofibrosis. Haematologica 103:e446-e449
Kleppe, Maria; Koche, Richard; Zou, Lihua et al. (2018) Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms. Cancer Cell 33:785-787
Qiu, Jiajing; Salama, Mohamed E; Hu, Cing Siang et al. (2018) The characteristics of vessel lining cells in normal spleens and their role in the pathobiology of myelofibrosis. Blood Adv 2:1130-1145
Pronier, Elodie; Cifani, Paolo; Merlinsky, Tiffany R et al. (2018) Targeting the CALR interactome in myeloproliferative neoplasms. JCI Insight 3:
Migliaccio, Anna Rita (2018) A vicious interplay between genetic and environmental insults in the etiology of blood cancers. Exp Hematol 59:9-13
Gupta, Vikas; Kosiorek, Heidi E; Mead, Adam et al. (2018) Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study. Biol Blood Marrow Transplant :
Gnanapragasam, Merlin Nithya; Crispino, John D; Ali, Abdullah M et al. (2018) Survey and evaluation of mutations in the human KLF1 transcription unit. Sci Rep 8:6587
Migliaccio, Anna Rita; Varricchio, Lilian (2018) Concise Review: Advanced Cell Culture Models for Diamond Blackfan Anemia and Other Erythroid Disorders. Stem Cells 36:172-179
Ling, Te; Crispino, John D; Zingariello, Maria et al. (2018) GATA1 insufficiencies in primary myelofibrosis and other hematopoietic disorders: consequences for therapy. Expert Rev Hematol 11:169-184

Showing the most recent 10 out of 195 publications